FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE 17 ACCORD 20 MEGA)

被引：6

作者：

Malka, David

Castan, Florence

Francois, Eric

Bouche, Olivier

Bennouna, Jaafar

Ghiringhelli, Francois

De La Fouchardiere, Christelle

Borg, Christophe

Samalin, Emmanuelle

Bachet, Jean Baptiste

Raoul, Jean-Luc

Cvitkovic, Frederique

Miglianico, Laurent

Bengrine-Lefevre, Leila

Dahan, Laetitia

Lecaille, Cedric

Aparicio, Thomas

Perrier, Herve

Gourgou, Sophie

Taieb, Julien

机构：

[1] Gustave Roussy, Villejuif, France

[2] Inst Canc Montpellier, Biometr Dept, Montpellier, France

[3] Ctr Antoine Lacassagne, Dept Med Oncol, F-06054 Nice, France

[4] Hosp Univ Robert Debre, Reims, France

[5] Inst Cancerol Ouest, Nantes, France

[6] Ctr Georges Francois Leclerc, Dijon, France

[7] Ctr Leon Berard, F-69373 Lyon, France

[8] CHU Minjoz, Med Oncol Unit, Besancon, France

[9] Digest Oncol CRLC Val dAurelle, Montpellier, France

[10] Ctr Hosp Univ Pitie Salpetriere, Paris, France

[11] Inst Paoli Calmette, Serv Oncol Med, Marseille, France

[12] Curie Rene Huguenin, St Cloud, France

[13] Ctr Hosp Prive St Gregoire, St Gregoire, France

[14] Hop St Antoine, F-75571 Paris, France

[15] Marseille Univ Hosp, Marseille, France

[16] Polyclin Bordeaux Nord Aquitaine, Bordeaux, France

[17] Hop Avicenne, Assistance Publ Hop Paris, F-93009 Bobigny, France

[18] Hop St Joseph, Marseille, France

[19] ICM Montpellier Canc Inst, CTD INCa, Biostat Unit, Montpellier, France

[20] APHP, Paris, France

[21] Paris Descartes Univ, Paris, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期

关键词：

D O I：

10.1200/jco.2015.33.15_suppl.4013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4013

引用

页数：1

共 50 条

[1] FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
Malka, David
Francois, Eric
Penault-Llorca, Frederique
Castan, Florence
Bouche, Olivier
Bennouna, Jaafar
Ghiringhelli, Francois
de la Fouchardiere, Christelle
Borg, Christophe
Samalin, Emmanuelle
Bachet, Jean-Baptiste
Raoul, Jean-Luc
Miglianico, Laurent
Bengrine-Lefevre, Leila
Dahan, Laetitia
Lecaille, Cedric
Aparicio, Thomas
Stanbury, Trevor
Perrier, Herve
Cayre, Anne
Laurent-Puig, Pierre
Gourgou, Sophie
Emile, Jean-Francois
Taieb, Julien
[J]. EUROPEAN JOURNAL OF CANCER, 2019, 115 : 97 - 106
[2] Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial.
Malka, D.
Gourgou-Bourgade, S.
Emile, J.
Laurent-Puig, P.
Taieb, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[3] A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma
Park, Haeseong
Wang-Gillam, Andrea
Suresh, Rama
Rigden, Caron E.
Amin, Manik A.
Tan, Benjamin R.
Pedersen, Katrina
Lim, Kian-Huat
Trikalinos, Nikolaos
Navo, Katherine
Morton, Ashley
Schrumpf, Lindsey
Marquez, Samantha
Trinkaus, Kathryn
Lockhart, A. Craig
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
[4] A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
Wainberg, Zev
Hecht, J. Randolph
[J]. CLINICAL COLORECTAL CANCER, 2006, 5 (05) : 363 - 367
[5] First-line panitumumab plus docetaxel and cisplatin in advanced gastric or gastroesophageal junction adenocarcinoma: Results of a phase II trial (SPIGA).
Aldana, Guillermo Alfonso Quintero
Folgar, Sonia Candamio
Mendez, Jose Carlos Mendez
Reboredo, Margarita
Fernandez, Monica Jorge
Constenla, Manuel
Reinoso, Carlos Romero
Fernandez, Mercedes Salgado
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] A phase II, open-label, randomized clinical trial of panitumumab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment in advanced biliary tract cancer: The Vecti-BIL study.
Leone, Francesco
Marino, Donatella
Filippi, Roberto
Cereda, Stefano
Belli, Carmen
Spadi, Rosella
Nasti, Guglielmo
Montano, Massimo
Amatu, Alessio
Aprile, Giuseppe
Cagnazzo, Celeste
Fasola, Gianpiero
Siena, Salvatore
Ciuffreda, Libero
Reni, Michele
Aglietta, Massimo
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[7] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Lui, Arthur Gregory Ang
Mulder, Karen E.
Brezden-Masley, Christine
Vickers, Michael M.
Monzon, Jose Gerard
Kennecke, Hagen F.
Goel, Rakesh
Ghosh, Sunita
Marginean, Horia
Vos, Larissa Joy
Raynard, SeeSee Juliana
Young, Kristine Lee
Fields, Anthony L. A.
Maroun, Jean Alfred
Spratlin, Jennifer L.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[8] An open-label phase II study of sorafenib and dacarbazine as first-line therapy in patients with advanced melanoma
Eisen, T.
Marais, R.
Affolter, A.
Lorigan, P.
Ottensmeier, C.
Robert, C.
Corrie, P.
Chevreau, C.
Erlandsson, F.
Gore, M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[9] Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma
Garcia, Jairo A.
Roberts, Lewis R.
[J]. JOURNAL OF HEPATOLOGY, 2012, 56 (02) : 486 - 487
[10] Phase II, Open-Label Study of Brivanib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma
Park, Joong-Won
Finn, Richard S.
Kim, Jun Suk
Karwal, Mark
Li, Ruby K.
Ismail, Fuad
Thomas, Melanie
Harris, Rosemarie
Baudelet, Christine
Walters, Ian
Raoul, Jean-Luc
[J]. CLINICAL CANCER RESEARCH, 2011, 17 (07) : 1973 - 1983

← 1 2 3 4 5 →